课题基金 / 基金详情

Targeting methyl-CpG-binding domain protein 2 (Mbd2) towards the development of next generation precision Epi-therapies against metastatic breast cancer

Targeting methyl-CpG-binding domain protein 2 (Mbd2) towards the development of next generation precision Epi-therapies against metastatic breast cancer
靶向甲基 CpG 结合域蛋白 2 (Mbd2)，开发针对转移性乳腺癌的下一代精准外延疗法
批准号：
472577
负责人：
Rabbani Shafaat A
金额：
$7.29万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-09-01 至 2023-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=472577&lang=en
关键词：
Breast Cancer Dna Methylation Mouse Models Transgenic Mice Tumour Metastasis

项目摘要

项目成果

Rabbani Shafaat A的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Breast cancer metastasis to distant organs in general and to the skeleton in particular are a major cause of cancer associated morbidity and mortality. These patients are generally in advanced stages when no effective therapies are available. Cancer initi
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of methyl-CpG-binding domain protein 2 (Mbd2) in breast cancer development, progression and metastasis
Targeting methyl-CpG-binding domain protein 2 (Mbd2) towards the development of next generation precision Epi-therapies against metastatic breast cancer
Urokinase plasminogen activator (uPA) and its receptor (uPAR) interaction in tumor microenvironment, therapeutic implications
DNA demethylation blockers; novel preventive and therapeutic approach to breast cancer development, progression and metastasis
  • 批准号：
    279668
  • 项目类别：
    Operating Grants
  • 资助金额：
    $58.14万
  • 财政年份：
    2013
  • 负责人：
    Rabbani Shafaat A
  • 依托单位：
    McGill University
海外基金